One place for the two questions that matter, is it legitimate, and can you get it. A live FDA tracker and a plain-English knowledge base, sourced and dated. Compounded, not FDA-approved.
Jul 23–24, 2026: the PCAC recommended six of seven peptides for the 503A Bulks List — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — and rejected Emideltide (DSIP), all against FDA staff advice. A recommendation is not approval, not authorization, and not availability.
See what the panel decided →The live FDA tracker: every peptide everyone's asking about, with the regulatory status and a plain-English availability verdict, two signals, never collapsed. Sourced, dated, updated as the landscape moves.
See the live trackerPlain-English monographs, graded honestly, what's proven, what's hype, what we still don't know. Browse by goal, by stack, or by molecule.
Browse the libraryWhichever door you pick, the same rule travels with you, two signals, never collapsed.
A peptide can be all over the news and still be unavailable. We show both, side by side, every time.
It lowered a barrier; it didn't open the door. A removed peptide is not yet legally compoundable.
A favorable July vote starts rulemaking, realistic earliest legitimate access is late 2026 into 2027.
Compounded medicines are made for one patient; they haven't been through FDA review for safety and efficacy. We say which is which, plainly.
The most viral peptides often have the least human evidence. We grade the evidence separately from the hype.
A few questions, and a licensed clinician maps a plan to your goals, only what's legitimately available, nothing you can't actually get.
One tap. We'll email you when a peptide's regulatory status or availability moves, what the rule says and whether you can get it, with the source.
Most peptides online ship under a “research use only: not for human consumption” label. That one phrase lets a seller skip FDA oversight, sterility testing, and any real manufacturing standard, and hands the entire risk to you.
Prescribed by a US-licensed clinician. Compounded in a US-licensed 503A/503B pharmacy to USP sterility and potency standards. Third-party tested every batch: identity, potency, and sterility. Monitored as an actual clinical relationship, not a one-time sale.
Compounded medications are not FDA-approved. Where that applies, we say so. Status and timelines are tracked openly on our FDA Tracker.
See exactly where every compound standsReviewed by the Peptós.LIFE clinical team · Last reviewed June 16, 2026. Statuses read live from the FDA Tracker dataset. Compounded medications are prepared for an individual patient and are not FDA-approved. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.